Skip to main content

Findings of PEXIVAS published in the NEJM

Findings of a global trial of plasma exchange and steroid dosing in autoimmune vasculitis (PEXIVAS) have recently been published in the New England Journal of Medicine.


Prof David Jayne
Professor David Jayne

Professor of Clinical Autoimmunity, University of Cambridge

PEXIVAS, led by David Jayne (Medicine) and sponsored by CUHFT, was the first global vasculitis study, recruiting from 120 sites across Europe, North America, Japan and Australia/New Zealand, and at over 700 patients was the largest vasculitis trial performed to date.

Severe, anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) is a rare disease of the immune system. There are two major problems that hinder the treatment of AAV. The first is a lack of treatment to bring the disease under control quickly before it causes major organ damage. The second is a high degree of treatment related toxicity.

PEXIVAS looked to examine these issues in patients with severe AAV. The research found that the use of plasma exchange did not reduce the incidence of death or end-stage kidney disease. A reduced-dose regimen of glucocorticoids was non-inferior to a standard-dose regimen with respect to death or end-stage kidney disease. Furthermore, reduced-dose glucocorticoids was associated with fewer serious infections after one year of treatment. These findings will impact on the treatment of these kidney and life threatening disorders.

For more information visit: School of Clinical Medicine

Published February 25, 2020

Latest from CCTU

New clues about irritable bowel syndrome found in the brain

Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.

Researchers eye up new gene therapy trial that could reverse hereditary blindness

Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (…

Artificial pancreas trialled for outpatients with type 2 diabetes for first time

An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis.

All news